141 related articles for article (PubMed ID: 35108518)
1. Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours: An integrated immunohistochemical analysis.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
Hum Pathol; 2022 Apr; 122():11-24. PubMed ID: 35108518
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathology of the luminal class of urothelial tumors.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
Sjödahl G; Eriksson P; Liedberg F; Höglund M
J Pathol; 2017 May; 242(1):113-125. PubMed ID: 28195647
[TBL] [Abstract][Full Text] [Related]
4. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.
Marzouka NA; Eriksson P; Rovira C; Liedberg F; Sjödahl G; Höglund M
Sci Rep; 2018 Feb; 8(1):3737. PubMed ID: 29487377
[TBL] [Abstract][Full Text] [Related]
5. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
Patschan O; Sjödahl G; Chebil G; Lövgren K; Lauss M; Gudjonsson S; Kollberg P; Eriksson P; Aine M; Månsson W; Fernö M; Liedberg F; Höglund M
Eur Urol; 2015 Nov; 68(5):824-32; discussion 835-6. PubMed ID: 25770486
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
7. Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer.
Koll FJ; Döring C; Herwig L; Hoeh B; Wenzel M; Cano Garcia C; Banek S; Kluth L; Köllermann J; Weigert A; Chun FK; Wild P; Reis H
J Clin Pathol; 2023 Nov; ():. PubMed ID: 37989554
[TBL] [Abstract][Full Text] [Related]
8. Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.
Sjödahl G
Methods Mol Biol; 2018; 1655():53-64. PubMed ID: 28889377
[TBL] [Abstract][Full Text] [Related]
9. The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma.
Marzouka NA; Eriksson P; Bernardo C; Hurst CD; Knowles MA; Sjödahl G; Liedberg F; Höglund M
J Mol Diagn; 2022 Sep; 24(9):992-1008. PubMed ID: 35853574
[TBL] [Abstract][Full Text] [Related]
10. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
[TBL] [Abstract][Full Text] [Related]
11. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
Cox A; Klümper N; Stein J; Sikic D; Breyer J; Bolenz C; Roghmann F; Erben P; Wirtz RM; Wullich B; Ritter M; Hölzel M; Schwamborn K; Horn T; Gschwend J; Hartmann A; Weichert W; Erlmeier F; Eckstein M
Eur Urol; 2024 Apr; 85(4):328-332. PubMed ID: 37031005
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.
Hardy CSC; Ghaedi H; Slotman A; Sjödahl G; Gooding RJ; Berman DM; Jackson CL
J Histochem Cytochem; 2022 May; 70(5):357-375. PubMed ID: 35437049
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
Benítez R; Yu K; Sirota M; Malats N; Pineda S
Front Immunol; 2023; 14():986598. PubMed ID: 36817478
[TBL] [Abstract][Full Text] [Related]
15. Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
Warrick JI; Sjödahl G; Kaag M; Raman JD; Merrill S; Shuman L; Chen G; Walter V; DeGraff DJ
Eur Urol; 2019 Jan; 75(1):18-22. PubMed ID: 30266310
[TBL] [Abstract][Full Text] [Related]
17. Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
Sirab N; Drubay D; Maillé P; Popova T; Ngo C; Gentien D; Moktefi A; Soyeux-Porte P; Pelletier R; Reyes C; Henry E; Pouessel D; Vordos D; Lebret T; de Reyniès A; Paoletti X; Radvanyi F; Allory Y
J Pathol; 2022 Jan; 256(1):108-118. PubMed ID: 34611919
[TBL] [Abstract][Full Text] [Related]
18. The Lund taxonomy for bladder cancer classification - from gene expression clustering to cancer cell molecular phenotypes, and back again.
Höglund M; Bernardo C; Sjödahl G; Eriksson P; Axelson H; Liedberg F
J Pathol; 2023 Apr; 259(4):369-375. PubMed ID: 36700594
[TBL] [Abstract][Full Text] [Related]
19. Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression.
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
J Clin Pathol; 2022 Nov; 75(11):766-771. PubMed ID: 34103388
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.
Jackson CL; Chen L; Hardy CS; Ren KY; Visram K; Bratti VF; Johnstone J; Sjödahl G; Siemens DR; Gooding RJ; Berman DM
J Pathol Clin Res; 2022 Mar; 8(2):143-154. PubMed ID: 34697907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
